We observed a steady increase in the use of immunotherapy for metastatic melanoma from 1.58% in 2011, the first year of approval of the new-generation immunotherapy for melanoma since interleukin-2 [2], to 58.03% in 2018. The gene discussed is IL2; the disease is melanoma.